PEG-Hemoglobin Trial Underway

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-ter clinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin, in cancer patients receiving radiation therapy. The agent was developed as a radiosensitizer to increase oxygenation of hypoxic tumors cells that may be resistant to irradiation. Patients will receive once-a-week infusions of PEG-hemoglobin followed by 5 days of radiation therapy, repeated weekly for 3 weeks.

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-terclinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin,in cancer patients receiving radiation therapy. The agent wasdeveloped as a radiosensitizer to increase oxygenation of hypoxictumors cells that may be resistant to irradiation. Patients willreceive once-a-week infusions of PEG-hemoglobin followed by 5days of radiation therapy, repeated weekly for 3 weeks.

Articles in this issue
Chemo Improves Pain Relief in Advanced Prostate Cancer
Multimedia Computer Program Patiently Answers Young Cancer Patients' Questions
NCCR Urges Congress to Support Senate Bill for Cancer Research
Researchers Propose New Treatment Guidelines for HIV
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Anderson
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samples
New Thinking on HIV Progression Leads to New Strategies
Hospitals Told Not to Capitate for 'Wrong' Reasons
More Study Needed of Possible Carcinogenesis of Winter Gas Additive
President Makes NCAB Appointments
Algorithm Identifies Women at Risk of Ovarian Cancer
Three Million a Year Die From Tobacco-Related Causes
Marketing of Cancer Services Must Include All Payer Modalities
Dr. Kessler Corrects Misapprehension That The FDA Cannot Regulate Tobacco Products
New Surgical Techniques May Reduce Impotence, Incontinence
Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.